Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Structure-specific endonuclease subunit SLX1 homolog B (SLX1B) is the catalytic subunit of the SLX1-SLX4 structure-specific endonuclease complex involved in resolving DNA secondary structures that arise during DNA repair and recombination.[1][2][3][8] SLX1B is critical in maintaining genome stability by introducing single-strand cuts at DNA junctions, such as 5'-flap structures and Holliday junctions, to facilitate repair.[1][8] It possesses GIY-YIG endonuclease activity and is primarily localized to the nucleus.[4][8] The gene has been implicated in regulation of genome stability, with some reported links to autism spectrum disorder in genetic studies, but is not recognized as a classical therapeutic target like receptors or kinases.[1][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Structure-specific endonuclease subunit SLX1 homolog B (SLX1B).